Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telisotuzumab vedotin versus docetaxel in previously treated c-Met overexpressing EGFR-wildtype non-squamous NSCLC
jRCT2031220047Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- May 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of telisotuzumab vedotin and docetaxel in non-small cell lung cancer (NSCLC) (2 arms), sponsored by AbbVie Inc. Primary endpoints: Progression-Free Survival per Independent Central Review and Overall Survival. Started May 2022; status: active, not recruiting.
02
Drugs
telisotuzumab vedotindocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031220047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220047.